Trump announces trade deal with EU following months of negotiations
On Tuesday, Stifel analysts upheld a Buy rating for BioMarin Pharmaceutical (TADAWUL:2070) Inc. (NASDAQ:BMRN) shares, with a steady price target of $91.00. According to InvestingPro data, the company maintains excellent financial health with a perfect Piotroski Score of 9 and trades at an attractive valuation relative to its growth potential. The firm’s confidence in BioMarin’s growth was bolstered by several factors discussed during a recent Biotech Bus Tour. The company’s Chief Financial Officer, Brian Mueller, and Investor Relations Officer, Traci McCarty, engaged in conversations that covered a range of topics central to BioMarin’s operations and strategy. This confidence appears well-founded, as BioMarin has achieved impressive revenue growth of 19.36% and maintains a robust gross profit margin of 81.01%.Want deeper insights? InvestingPro subscribers have access to over 30 additional premium metrics and analysis tools for BMRN.
The discussions included the growth potential of BioMarin’s drug Voxzogo and the company’s strategy to expand the franchise amidst competition. Another key point was BioMarin’s decision to conduct a superiority trial for BMN333, a treatment for Achondroplasia. Additionally, the rationale behind BioMarin’s recent acquisition of INZY and its openness to further business development was elaborated upon.
BioMarin’s legacy Enzyme Replacement Therapy (ERT) business, particularly the drug Palynziq, was highlighted for its underappreciated growth profile. The company has reorganized into business units with clear responsibilities, which has positively impacted Palynziq’s performance. The topics that garnered the most investor interest were the prospects of Voxzogo and BMN333.
Stifel’s analysis suggests that the current stock price reflects a very conservative outlook for BioMarin. The analysts anticipate that 2026 will be a pivotal year for the company to counteract any negative perceptions, especially as competitor Ascendis Pharma (NASDAQ:ASND)’s Transcon-CNP poses a potential challenge to BioMarin’s otherwise strong market execution. Based on comprehensive analysis from InvestingPro, BioMarin currently appears undervalued, suggesting potential upside for investors who act before the market recognizes its full value.
In other recent news, BioMarin Pharmaceutical Inc. announced its acquisition of Inozyme Pharma for approximately $270 million in cash, marking a strategic expansion of its enzyme replacement therapy portfolio. The acquisition includes INZ-701, a Phase 3 candidate for treating ENPP1 deficiency, a rare genetic disorder. Analysts from Bernstein have maintained an Outperform rating on BioMarin, raising the price target to $95, while TD Cowen reiterated a Buy rating with a $120 target, citing the acquisition’s strategic fit and potential. Evercore ISI also held its Outperform rating with a $105 target, describing the transaction as a savvy move that leaves BioMarin with resources for further opportunities. The deal is anticipated to close in the third quarter of 2025, with pivotal trial data for INZ-701 expected in early 2026 and a potential market launch in 2027. Stifel analysts highlighted the commercial potential of INZ-701, estimating peak sales between $400 million and $600 million. BioMarin’s CEO, Alexander Hardy, emphasized the acquisition’s alignment with the company’s commitment to developing therapies for serious genetic conditions. The transaction reflects BioMarin’s ongoing strategy to enhance its pipeline and strengthen its position in the treatment of rare diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.